Core Insights - The mRNA cancer vaccines and therapeutics market is projected to grow from $52.85 billion in 2023 to $61.52 billion in 2024, with a compound annual growth rate (CAGR) of 16.4% [2][11] - By 2028, the market size is expected to reach $113.41 billion, reflecting a CAGR of 16.5% [2][11] Market Growth Drivers - Growth in the mRNA cancer vaccines and therapeutics market is driven by factors such as changing lifestyles, increased funding in medical research, favorable regulatory environments, established healthcare infrastructures, and ongoing development of new therapeutic pipelines [3] - Promising clinical trial results, rising awareness of mRNA technology, significant unmet medical needs, and the potential for improved patient outcomes are expected to further fuel market growth [4][5] Market Trends - Anticipated trends include expansion into new therapeutic areas, personalized medicine approaches, advancements in mRNA delivery systems, development of multivalent mRNA vaccines, and integration of artificial intelligence in mRNA design [4] - The increasing prevalence of cancer, influenced by sedentary lifestyles and environmental factors, is expected to drive demand for mRNA cancer vaccines and therapeutics [5] Competitive Landscape - Leading companies in the mRNA cancer vaccines and therapeutics market include Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis SA, and Moderna Therapeutics Inc., among others [6][8] - Companies are focusing on innovative treatments, particularly mRNA cancer vaccines, to meet the rising demand for effective cancer therapies [6] Regional Insights - North America was the largest market for mRNA cancer vaccines and therapeutics in 2023, while Asia Pacific is anticipated to be the fastest-growing region in the forecast period [9]

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. So what: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Moderna, Inc. securities between January 18, 2023, and June 25, 2024, of the upcoming lead plaintiff deadline on October 8, 2024, for a class action lawsuit related to misleading statements about the effectiveness of their RSV vaccine [2][5]. Group 1: Class Action Details - Investors who bought Moderna securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 8, 2024 [3]. - The lawsuit alleges that Moderna made false and misleading statements regarding the effectiveness of its mRNA-1345 RSV vaccine, which was claimed to be less effective than represented [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [4].

Group 1: Moderna's Norovirus Vaccine Study - Moderna has initiated the phase III Nova 301 study for its mRNA norovirus vaccine candidate, mRNA-1403, with the first participant dosed in the United States [1] - The study aims to enroll approximately 25,000 participants globally, focusing on older adults at higher risk of norovirus infection [2][3] - Norovirus is highly contagious and a leading cause of diarrheal disease, resulting in around 200,000 deaths annually [3] Group 2: Partnership in Taiwan - Moderna has entered a joint agreement with Cenra Healthcare to promote its mRNA respiratory vaccine portfolio in Taiwan, including the COVID-19 vaccine, Spikevax [4] - Moderna will handle the manufacturing and distribution of the vaccines, while Cenra Healthcare will manage promotion and education activities [5] Group 3: Stock Performance and Rankings - Moderna's shares have decreased by 32.8% this year, contrasting with a 1.8% decline in the industry [2] - Currently, Moderna holds a Zacks Rank of 3 (Hold), while other biotech stocks like ANI Pharmaceuticals, Krystal Biotech, and Fulcrum Therapeutics have higher rankings [6]

Core Insights - Klotho Neurosciences, Inc. has announced the addition of Dr. Robert Langer to its Scientific Advisory Board, highlighting his belief in the company's mission and potential in developing therapies for neurodegenerative diseases [1][4] Company Overview - Klotho Neurosciences is focused on innovative therapies for neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's disease, leveraging research on the Klotho protein, which has shown neuroprotective potential in preclinical models [3][5] - The company holds patents for its secreted form of Klotho (s-KL) in the USA, Europe, Hong Kong, and China, indicating a strong intellectual property position [3] Dr. Robert Langer's Role - Dr. Langer is a prominent figure in biotechnology, known for his contributions to drug delivery systems and mRNA-based therapeutics, including the COVID-19 vaccine [2] - His involvement is expected to provide significant guidance on the scientific and clinical development of Klotho Neurosciences' product candidates, marking a milestone for the company [4] Strategic Direction - The company aims to position itself at the forefront of addressing the challenges of treating neurodegenerative diseases, with Dr. Langer's expertise seen as invaluable for advancing its pipeline [4]

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Repair Biotechnologies, a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced they have entered into a collaboration and nonexclusive license agreement to combine Repai ...

NEW YORK, Sept. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=105022&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=104511&from=3 CLASS PERIOD: January 18, 2023 to Ju ...